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Abstract
Background: Warfarin is an oral anticoagulant medication that disrupts the liver’s production of clotting factors.
While this medication is highly effective for the prevention of thromboembolic events, it also has a narrow
therapeutic range and a vulnerability to interactions with other drugs and vitamin K-containing foods. Warfarin is
commonly ingested at dinnertime, the same time of day that dietary vitamin K consumption (found largely in
green leafy vegetables) is most variable. While the long half-life of warfarin might make this irrelevant, the ultra
short half-life of vitamin K and the possibility of a hepatic first-pass effect for warfarin make it worth evaluating
whether morning ingestion of warfarin, when vitamin K levels are consistently low, leads to greater stability of its
anticoagulant effect. An examination of the timing of administration on the effectiveness of warfarin has never
before been conducted.
Methods/design: This is a 7-month Prospective Randomized Open Blinded End-point (PROBE) study in which
established evening warfarin users (primary care managed Canadian outpatients in the provinces of British Columbia
and Alberta) will be randomized to either switch to morning ingestion of warfarin (the intervention) or to continue
with evening use (the control). The primary outcome is the percent change in the proportion of time spent outside
the therapeutic range of the international normalized ratio (INR) blood test. Secondary outcomes include change in
proportion of time spent within the therapeutic INR range (TTR), percentage of patients with TTR >75 %, percentage of
patients with TTR <60 %, and major warfarin-related cardiovascular events (including all-cause mortality, hospitalization
for stroke, hospitalization for GI bleeding, and deep venous thrombosis/pulmonary embolism). We will also compare
whether day-to-day variability in the consumption of high vitamin K-containing foods at baseline affects the baseline
TTR in this cohort of evening warfarin users.
Discussion: This study addresses whether the timing of warfarin ingestion influences the stability of its anticoagulant
effect. Should morning ingestion prove superior, the safety and effectiveness of this medication, and hence the
prevention of stroke, pulmonary embolus, and major hemorrhage, could potentially be improved with no added cost
or inconvenience to the patient.
Trial registration: ClinicalTrials.gov: NCT02376803. Registered on 25 February 2015.
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Background
Vitamin K is obtained primarily from green leafy vegeta-
bles (in particular kale, spinach, chard, beet greens, broc-
coli, cabbage, romaine lettuce, and Brussels sprouts) [1].
It is an essential cofactor used by the liver to “activate”
the clotting factors it releases into the blood. Vitamin K
has a very short half-life in the body (approximately 2 ½
hours) and cycles through an active (so far as its ability
to “activate” clotting factors) and inactive form in the
liver [2]. Warfarin acts by preventing one of the inter-
mediary steps necessary to convert the inactive form of
vitamin K back to the active form and hence it reduces
the amount of available activated clotting factor [1].
When vitamin K is first ingested, however, it is in an eas-
ily activated form upon which warfarin has little effect
[2]. As a result, consumption of high vitamin K-
containing foods can counteract the effect of warfarin,
and highly variable consumption of these foods may
cause clinically important INR variability in some indi-
viduals [3].
The effectiveness of the anticoagulant warfarin is mea-
sured by the international normalized ratio (INR) blood
test, which indicates how long it takes the user’s blood
to clot compared to normal [1]. Canadian warfarin users
typically have their INR measured by their family phys-
ician every 1–4 weeks, and same-day changes in warfarin
dosing are made in response to that day’s INR test. In
order to shorten the response time for making a dosing
change, patients are traditionally advised to have their
INR test in the morning and to take their warfarin in the
evening (so that the INR test result will be back in time
to change that day’s warfarin dose if needed). However,
this leads to taking warfarin at the same time of day as
the most highly variable consumption of vitamin K.
Conceivably, if warfarin activity is greater around the
time of ingestion, when liver concentrations would be
highest, taking warfarin in the morning (when the vita-
min K content of typical breakfast foods is consistently
low) might lead to greater stability in anticoagulant ef-
fect. The question of whether the time of ingestion of
warfarin matters to INR stability has never been formally
addressed.
We are conducting a pragmatic randomized con-
trolled trial (RCT) of morning versus evening war-
farin ingestion to determine whether the timing of
warfarin ingestion matters to the stability of its anti-
coagulant effect.
Hypotheses
Our hypotheses are as follows:
1. Morning, as compared to evening, administration of
warfarin will produce a more consistent
anticoagulant effect and improve the proportion of
time a patient spends in the target therapeutic INR
range (TTR = time in therapeutic range).
2. A less variable day-to-day dietary vitamin K
consumption at dinner, whether consistently high
or consistently low, will reduce variability in the
anticoagulant effect of warfarin and improve the
proportion of time a patient spends in the target
therapeutic INR range.
Aims
This study has the following aims:
1. To determine (by RCT) whether switching current
warfarin users from evening to morning dosing will
alter the proportion of time spent in the therapeutic
INR range
2. To determine (by cross-sectional analysis of baseline
data) whether evening warfarin users with greater
variability in daily dinnertime vitamin K ingestion
have a lower time in the therapeutic INR range
3. To determine by prospective subgroup analysis of
RCT data whether the effect of warfarin timing on
TTR (i.e., the effect of changing to morning dosing)




This is a Prospective Randomized Open Blinded End-point
(PROBE) study [4] conforming to Consolidated Standards
of Reporting Trials (CONSORT) guidelines. A CONSORT
Flow Diagram is included as Additional file 1.
Ethics approval was obtained from the Health Research
Ethics Board at the University of Alberta (Pro00050057)
and the Clinical Research Ethics Board at the University of
British Columbia (H14-03124). No modifications to the
approved protocol are anticipated.
Recruitment
Participating community family physicians in the Canad-
ian provinces of British Columbia and Alberta will send
a letter of invitation to all warfarin-using patients under
their care with the exception of those whom they view
as palliative or deemed incapable of informed consent.
This letter: (1) describes the project, (2) lets patients
know their physician’s office is participating, and (3) pro-
vides a central contact number that reaches our study
coordinator for more information if they are interested.
The study coordinator dialogs with interested patients
who call in, screens them for eligibility, and obtains writ-
ten informed consent (via online REDCap survey or
mail-in consent form) from all patients willing to be ran-
domized. For consenting participants who meet the
screening criteria for eligibility, the family physician will
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be asked to provide investigators with the participant’s
target INR range and their last 6 months of INR results,
test dates, and warfarin dosing.
Data collection and management
Study data will be collected, managed, and securely main-
tained using REDCap electronic data capture tools hosted
by the Women and Children's Health Research Institute
at the University of Alberta [5]. Non-electronic personal
information of potential and enrolled patients (consisting
of INR results and INR flow sheets faxed to us by family
physicians) will be kept in a locked fireproof cabinet ac-
cessible only to the study investigators and staff. All study
data (including INR results) will be archived in REDCap
and maintained for a minimum of 5 years.
Inclusion and exclusion criteria
Study inclusion criteria include: (1) dinner or evening
use of warfarin, (2) ≥3 months of continuous warfarin
use, (3) expectation of long-term warfarin use, (4) base-
line INR data (last 6 months if available, minimum 3
months) with at least four evaluable INR results no more
than 8 weeks apart provided to the study team by
patient’s family physician, and (5) community dwelling.
Exclusion criteria include patients under palliative care
or those who are unable to provide informed consent in
the opinion of the treating family physician.
Randomization and allocation
Upon receiving eligible baseline INR data, consented eli-
gible participants are contacted by a study coordinator
via telephone to obtain baseline information presumed
to be predictive of TTR. This includes age ≥80 years,
hospitalization in the last 6 months, temporary planned
discontinuation of warfarin in the last 6 months (e.g., for
elective surgery), number of daily prescription medica-
tions, <6 months of warfarin use, the self-reported
average number of days per week in which high vitamin
K-containing foods are consumed, and how variable the
participant feels this estimated level of vitamin K con-
sumption is (on a 4-point scale). This study coordinator
(who has no clinical patient interactions) then random-
izes the participant, using the REDCapTM randomization
module to ensure allocation concealment, to interven-
tion or control [5]. Randomization will employ variable
blocks of 2 or 4 and will be stratified by the proportion
of baseline INR readings within the therapeutic range
(<50 %, 50–80 %, >80 %).
Intervention and blinding
Active arm subjects will switch their warfarin use to
morning. The control arm will continue with their
current pattern of evening use. There are no run-in or
washout periods in this study. Participants randomized
to morning warfarin ingestion will be asked to make
the change 5 days prior to their next scheduled INR
test (so that any deviation in the INR can be detected
early). Although patients and their physicians will be
aware of treatment assignment, our study evaluators
will be blinded to allocation.
On-study participant interaction
Participants have the option to interact with study staff
either online (via online consent and online follow-up
surveys using REDCap) or in person (via mailing in con-
sent and having follow-up interviews over the phone
where study staff record their responses in REDCap).
Following the randomization telephone interview, such
online or in-person follow-up interviews then occur at 1
week, 1 month, and 7 months (relative to the expected
date of first morning ingestion of warfarin in those allo-
cated to morning use, or relative to the date of
randomization in those allocated to control). During
these interviews participants self-report their adherence
to the allocated timing of warfarin ingestion, as well as
any illnesses and potentially warfarin-related adverse
events (bleeding and thromboembolic events). Patients
are encouraged to adhere to the allocated intervention
during telephone follow-up, and suggestions to facili-
tate adherence at the time of allocation include: (1)
helping to set a routine by placing their warfarin near
objects that they interact with at the relevant time of
day (e.g., other medications, toothbrush, false teeth,
coffee pot/kettle/toaster), (2) using a dosette box with
time of day divisions, (3) setting an alarm, (4) asking
their spouse to remind them, and (5) offering to have
study staff remind them the day before any switch to
morning warfarin is supposed to occur. Decisions on
discontinuing warfarin or returning to evening dosing
in response to perceived harm, or upon patient re-
quest, will be made entirely by the treating physician
at their discretion. The same is true for any decisions
related to concomitant care. Participants are free to
withdraw from the study at any time without penalty
and can decide to have their data excluded from, or
continue to be included in, the analysis.
Outcomes
Seven months after randomization of each patient, we
will ask their family physician to provide us all INR re-
sults for that period in order to determine the following
outcomes during the last 6 months of therapy.
Primary outcome
The primary outcome is percentage change in time
spent outside the family physician’s target INR range for
that patient. This primary outcome has been chosen be-
cause we believe this is a measure more likely to be
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shared by patients across a wide range of TTR. It is also
the time spent outside of range that contributes more
directly to risk of thrombosis and hemorrhage; hence,
the change in this measure is more clinically meaningful
than the change in TTR itself.
Secondary outcomes
The secondary outcomes are:
1. Change in TTR
2. Percentage of patients with TTR >75 %
3. Percentage of patients with TTR <60 %
4. For those patients with at least one INR value above
the therapeutic range, the maximum INR value
observed
5. For those patients with at least one INR value below
the therapeutic range, the minimum INR value
observed
6. Percentage of time spent above the therapeutic
range
7. Percentage of time spent below the therapeutic
range
8. Major warfarin-related cardiovascular events
(including all-cause mortality, hospitalization for
stroke, hospitalization for GI bleeding, and deep
venous thrombosis/pulmonary embolism)
The percentage of patients with TTR >75 % provides
the percentage of patients considered to have excellent
control, while the percentage of patients <60 % provides
the percentage of patients for whom other anticoagula-
tion strategies may be indicated [6, 7]. Maximum and
minimum INR values provide a sense of how far out of
range patients go, while major warfarin-related cardio-
vascular events aggregate outcomes that might stem
from both inadequate and excessive anticoagulation.
Safety outcomes
The safety outcomes, as initially flagged from patient in-
terviews and confirmed with family physicians, are:
1. Major thromboembolic events (including non-
hemorrhagic stroke, deep vein thrombosis, pulmon-
ary embolus, and acute arterial occlusion)
2. Major bleeding events (includes all bleeding events
requiring hospitalization or transfusion such as
hemorrhagic stroke and GI bleeding).
As this study is small, relatively low risk, and of short
duration, there will be no interim safety analysis and
hence no formal data safety monitoring board.
The occurrence of major adverse events will be re-
ported to the principal investigator, who will determine
the appropriate action should a signal of harm in the
intervention group arise.
Sample size
We wish to be able to demonstrate a 20 % reduction in
time out of therapeutic range and will conservatively es-
timate (since there are no prior studies exploring this
outcome to guide us) that the standard deviation of this
measure is twice the mean effect (i.e., SD = 40 %). For a t
test with 1:1 allocation to the control and experimental
groups, power = 0.9, alpha = 0.05, minimum difference =
20 %, and SD = 40 %, the required sample size per group
is 85 (i.e., 170 subjects in total). Providing for potential




The therapeutic INR range for each patient will vary and
be determined by the treating physician. Typically the
therapeutic range is 1 unit wide (often 2–3 or 2.5–3.5),
but some physicians will choose narrower or wider
ranges (e.g., 3.0–3.5 or 2–3.5). We will standardize the
width of all target ranges by determining the midpoint
of each patient’s individual target range and use upper
and lower limits that are 0.5 unit above and below this
midpoint. For example, if a physician is targeting a nar-
rower than normal 3.0–3.5 range, we will use a midpoint
of 3.25 and assume a (standardized width) target thera-
peutic range of 2.75–3.75. The proportion of time both
in and out of therapeutic range will be determined using
the linear interpolation method of Rosendaal, which
(conceptually) draws a line between sequential INR
values no more than 8 weeks apart and assigns a pro-
jected INR value to every day in that interval [8].
RCT
All analyses will be by intention to treat. The primary
analysis of percentage change in time outside of thera-
peutic range will be by Student’s t test if the data appear
to be normally distributed or by Mann-Whitney U test if
they are not. As percentage change in time outside of
therapeutic range can only be calculated for patients for
whom the time outside normal range is not zero, this
analysis will exclude anyone who was in range 100 % of
the time at baseline. The secondary analyses will be by
Student’s t test or Mann-Whitney U test (for percentage
change in TTR, maximum and minimum INR values,
and percentage of time spent above and below target
range) and by Student’s t test or Fisher’s exact test (for
both percentages of patients with TTR >75 % and <60 %,
and major warfarin-related cardiovascular events). A
subgroup analysis of the influence on the intervention of
the numbers of days per week that high vitamin K foods
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are ingested will be carried out looking at an ANOVA
analysis of percent change in time outside of therapeutic
range according to three possible categories for the
number of days per week of consumption of high vita-
min K-containing foods (these being less than 2, 2 to 5,
and greater than 5 days per week). In the same analysis
we will also examine the effect on the intervention of
the patient’s global assessment of how variable their con-
sumption of high vitamin K containing foods is. To do
this, we will convert the 4-point scale of possible re-
sponses into a dichotomous variable that combines the
two options indicating the most variable diet and the
two options indicating the least variable diet.
Baseline cross-sectional analysis
The effect on baseline TTR of the number of days per
week that high vitamin K-containing foods are con-
sumed will be analyzed with multiple linear regression
using baseline covariates which include: gender, age ≥80
years, hospitalization in the last 6 months, temporary
planned discontinuation of warfarin in the last 6
months, number of daily prescription medications, <6
months of warfarin use, each of the three possible cat-
egories for number of days per week consuming high
vitamin K-containing foods, and the patient’s dichotom-
ous global assessment of how variable their pattern of
vitamin K consumption is.
Discussion
There are no studies or systematic reviews evaluating
the optimal timing of warfarin dosing. The assumption
that evening use will lead to more stable INR manage-
ment (by more prompt dose adjustment) has never been
tested. Given that vitamin K interferes with the effective-
ness of warfarin, it is conceivable that matching the time
of greatest warfarin activity to the period of most con-
sistent vitamin K availability (i.e., taking warfarin at
breakfast) might lead to greater stability in warfarin's
anticoagulant effect.
Warfarin is widely prescribed (often to older adults
with multiple comorbidities), and patients receiving this
medication are most commonly managed by their family
physician. Conducting this pragmatic trial in “real-
world” community primary care practices serves to
maximize the generalizability of our findings.
This study has the potential to benefit both our study
participants and the population of warfarin users world-
wide. This potential benefit must be weighed against the
potential risk to participants (during the 7 months of
trial participation) from an anticipated extra 8 to 12
hours delay between learning the results of an INR test
and adjusting a dose accordingly. Because the usual
interval between tests is 1 to 4 weeks, and given the
short duration of this trial, we believe this is not an
unreasonable risk when weighed against the potential
benefit of improved prevention of stroke and other
thromboembolic events over the longer term.
Dissemination of findings
An interactive executive summary webinar will be made
available to all trial participants consenting to be con-
tacted with our study findings, and trial results will be
posted on the Pragmatic Trials Collaborative website for
the public to peruse. All participating clinics, physicians,
and consenting participants will additionally be informed
of the results via email or letter mail. If the trial findings
are clinically impactful, they will be more broadly dis-
seminated via the Best Science Medicine Podcast and
Tools for Practice evidence summaries, which are
emailed directly to subscribing family physicians (both
of these knowledge translation vehicles are co-produced
by members of our investigative team). The Pragmatic
Trials Collaborative will further disseminate any mean-
ingful findings to its physician members and to its sup-
porting partner organizations. Regardless of the impact
of the findings, a manuscript will be prepared and sub-
mitted to a peer-reviewed journal. Upon publication of
the last planned manuscript stemming from this work,
anonymized patient level data will be made available on-
line for use by other researchers.
Trial status
Recruitment started in February 2015. Patients are still
being recruited at the time of submission.
Additional file
Additional file 1: INRange CONSORT flow diagram. (DOCX 191 kb)
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